7 fortune
Expansion of One-Stop Dataset of Physical Banking Facilities of Retail Banks in Hong KongDumka: Non-teaching staff of the Sidho Kanhu Murmu University (SKMU) in Dumka cranked up its ongoing agitation on Wednesday by locking the main gate of the university’s headquarters and its constituent colleges. The protests have been ongoing since November 26. The protests, being staged to demand the implementation of seventh pay-scale which is allegedly due for eight years now, assured career progression (ACP) and modified assured career progression (MACP) benefits. However, the move paralysed the academic activities of postgraduate and undergraduate courses across all SKMU campuses. The deadlock began when SKMU management discontinued ACP and MACP, being paid from internal resources, citing a notification issued by human resources development (HRD) declaring it's helplessness to allocate funds against the same on the pretext of financial burden on the ex-chequer. Although the non-teaching staff union termed the move to be uncalled for, it was prompted to launch the strike demanding the implementation of at least the seventh pay-scale from internal resources until the HRD comes forward with the pay fixation of individual staffs of third and fourth categories which is pending for long. Terming the demands of the agitating staffs to be genuine, the SKMU administration has written to the Raj Bhavan seeking approval from governor-cum-chancellor Santosh Gangwar for the benefits of the seventh pay-scale to the non-teaching staffs to be paid from internal resources. Netlal Mirdha, general secretary of SKMU non-teaching employees’ union, said: “The SKMU is paying crores in various heads without seeking Raj Bhavan’s permission. This move only reflects SKMU’s apathy towards its employees.” We also published the following articles recently SKMU non-teaching staff step up protests Non-teaching staff at Sidho Kanhu Murmu University (SKMU), Dumka, locked down the university and its colleges on Wednesday, escalating their protest for the implementation of the seventh pay scale and other benefits. The strike, ongoing since November 26th, has paralyzed academic activities. Patna University classes paralysed as non-teaching staff go on strike Non-teaching staff at Patna University launched an indefinite strike on Thursday, halting academic and administrative work. Examinations at the law college proceeded after authorities opened a locked gate. BFA exams also occurred without disruption. Strikers locked university buildings Wednesday night, preventing classes. They demand compassionate appointments for dependents of deceased staff and a career promotion scheme. PU non-teaching employees strike enters 3rd day Non-teaching employees of Patna University (PU) continued their indefinite strike for a third day, disrupting academic activities and examinations. Demands include payment of revised pay scale arrears, implementation of career progression, and compassionate appointments. Talks between the university and employees have failed. The strike has locked down colleges, departments, and administrative units, leaving the campus deserted. Stay updated with the latest news on Times of India . Don't miss daily games like Crossword , Sudoku , and Mini Crossword .Indian stock market shows resilience, growth potential amid cautiously optimistic outlook — expert advice
Trump says he can't guarantee tariffs won't raise prices, won't rule out revenge prosecutions
None
Gayle Williams-Brett, right, is frequently overwhelmed by the responsibility of caring for her severely disabled mother, who lives with her in a two-story brownstone in Brooklyn. She says she has often felt alone as a full-time caregiver. Cornell Antoine for The Washington Post Gayle Williams-Brett, 69, plans to tackle a project she’s been putting off for months: organizing all her financial information. Michael Davis, 71, is going to draft a living will and ask a close friend to be his health-care surrogate and executor of his estate. These seniors have been inspired to take these and other actions by an innovative course for such “solo agers”: Aging Alone Together, offered by Dorot, a social services agency in New York City. Most of them live alone, without a spouse, a partner or adult children to help them manage as they age. Until a few years ago, few resources were available for this growing slice of the older population. Now, there are several Facebook groups for solo agers, as well as in-person groups springing up across the country, conferences and webinars, a national clearinghouse of resources and an expanding array of books on the topic. All address these seniors’ need to connect with others, prevent isolation and prepare for a future when they might become less robust, encounter more health issues and need more assistance. EASING ISOLATION “Older adults who cannot rely on family members need to be very intentional about creating support systems and putting other plans in place,” said Ailene Gerhardt, a patient-advocate in Boston who created the Navigating Solo Network three years ago. In a survey published last year, AARP – which broadens the definition of older Americans to people 50 and beyond – examined those who live alone and don’t have living children. Ten percent of people 50 or older meet this definition, AARP estimates. An additional 11 percent have at least one living child but are estranged from them. And 13 percent have children who they believe can’t or won’t help them manage their finances and health care. Preparing in isolation for the future can be daunting. “If solo agers don’t feel they have people to talk to as they craft their aging plan, they often will skip the whole process,” said Gerhardt, who endorses a group planning model for these seniors. That’s the format Dorot has adopted for its free course Aging Alone Together, which is available nationally online and in person in New York. More than 1,000 people have participated in the program since it was launched in 2021. Dorot is working with partners across the country to expand its reach. The program consists of six 90-minute, online interactive weekly sessions that focus on the seniors’ key concerns: building communities of support, figuring out where to live, completing advance care directives such as living wills, and getting financial and legal affairs in order. One goal is to help participants identify priorities and overcome the fear and hesitation that so many older adults feel when peering into their uncertain futures, said Claire Nissen, a Dorot staffer who runs the program. Another is to offer practical tools, advice and resources that can spur people to action. Yet another is to foster a sense of community that promotes a can-do attitude. As Nissen said repeatedly when I took the course in September and October, “Solo aging doesn’t mean aging alone.” PLANNING FOR THE FUTURE That message resonated deeply with Williams-Brett, who lives with her severely disabled mother, 97, in a two-story brownstone in Brooklyn. Williams-Brett, who is divorced and never had children, expects to be on her own as she grows older. Her mother had a devastating stroke three years ago, and since then Williams-Brett has been her full-time caregiver. Overwhelmed by everything on her to-do list – declutter the house, make home repairs, straighten out her finances, safeguard her mother’s health – Williams-Brett told me she’d been struggling with shame and fear. Hearing other seniors voice similar concerns during Aging Alone Together sessions, Williams-Brett realized she didn’t judge them as she was judging herself. “I thought, we all have issues we’re dealing with,” she said. “You don’t have anything to feel ashamed of.” Kromrey, who lives alone in Tampa, knows he’s fortunate to be healthy, financially stable and very close with his adult daughter, who will be his health-care and legal decision-maker if he becomes incapacitated. Kromrey, widowed nine years ago, also has three sons – two in South Carolina and one in West Palm Beach, Florida. While participating in Aging Alone Together, Kromrey realized he had assumed he would never have a health crisis such as a stroke or heart attack – a common form of denial. His daughter and her husband planned to travel from North Carolina to join Kromrey over Thanksgiving. During that visit, Kromrey said, he would give her passwords to his computer and online accounts, explain his system for keeping track of bills, and show her where other important files are. “That way, she’ll just be able to take right over if something unexpected occurs,” he said. Davis is an artist who never married, doesn’t have siblings and lives alone in Manhattan. In a phone conversation, he said his most pressing concern is “finding something to do that’s worthwhile” now that arthritis has made it difficult for him to paint. In some ways, Davis is prepared for the future. He has a long-term care insurance policy that will pay for help in the home and a rent-regulated apartment in a building with an elevator. But he recognizes that he’s become too isolated as his artistic activities have waned. “There are days that go by when I don’t say a word to anyone,” Davis acknowledged. “I have my friends, but they have their own lives, with their children and grandchildren. I’m turning to Dorot for more social contact. And Aging Alone Together has helped me focus on the here and now.” RESOURCES For more information about Aging Alone Together, email agingalonetogether@dorotusa.org or visit the program’s website at dorotusa.org/agingalonetogether. A national clearinghouse of resources for solo agers and information about solo-ager groups in the United States is available at the Navigating Solo website. The National Council on Aging has assembled a guide to resources and support for older adults living alone on its website, ncoa.org. Facebook groups for solo agers include Elder Orphans (Aging Alone), Elder Orphans, NYC Solo Agers and Solo Aging Without Personal Representative. Another online community is The Solo Ager/Aging Together. Books about planning for solo aging include “Essential Retirement Planning for Solo Agers,” “Solo and Smart,” “Who Will Take Care of Me When I’m Old?” and “The Complete Eldercare Planner.” Several videos about planning for solo aging can be found on YouTube, including a helpful video from CJE SeniorLife. Comments are not available on this story. Send questions/comments to the editors. « PreviousSpecial Counsel Jack Smith on Monday moved to dismiss the federal cases against US President-elect Donald Trump -- including one for election subversion -- citing an official policy of not prosecuting a sitting president. Trump, 78, was accused of conspiring to overturn the results of the 2020 election he lost to Joe Biden and mishandling classified documents after leaving the White House, but neither case ever came to trial. Smith, in a filing with the district judge in Washington presiding over the election case, said it should be dropped in light of the long-standing Justice Department policy of not indicting or prosecuting a sitting president. He cited the same reasoning in withdrawing his appeal of a ruling by a district judge, a Trump appointee, who dismissed the classified documents case earlier this year. Smith asked District Judge Tanya Chutkan to dismiss the election interference case "without prejudice" -- leaving open the possibility it could be revived after Trump leaves office four years from now. The special counsel paused the election interference case this month after Trump defeated Vice President Kamala Harris in the November 5 presidential election. "The Government's position on the merits of the defendant's prosecution has not changed," Smith said in the filing with Chutkan. "But the circumstances have." "It has long been the position of the Department of Justice that the United States Constitution forbids the federal indictment and subsequent criminal prosecution of a sitting President," Smith said. "As a result this prosecution must be dismissed before the defendant is inaugurated." In a separate filing, Smith said he was withdrawing his appeal of the dismissal of the classified documents case against Trump but pursuing the case against his two co-defendants, Trump valet Walt Nauta and Mar-a-Lago property manager Carlos De Oliveira. - 'Empty and lawless' - Trump, in a post on Truth Social, said the cases were "empty and lawless, and should never have been brought." "Over $100 Million Dollars of Taxpayer Dollars has been wasted in the Democrat Party's fight against their Political Opponent, ME," he said. "Nothing like this has ever happened in our Country before." Trump is accused of conspiracy to defraud the United States and conspiracy to obstruct an official proceeding -- the session of Congress called to certify Biden's win, which was violently attacked on January 6, 2021 by a mob of the then-president's supporters. Trump is also accused of seeking to disenfranchise US voters with his false claims that he won the 2020 election. The former and incoming president also faces two state cases -- in New York and Georgia. He was convicted in New York in May of 34 counts of falsifying business records to cover up a hush money payment to porn star Stormy Daniels on the eve of the 2016 election to stop her from revealing an alleged 2006 sexual encounter. Judge Juan Merchan has postponed sentencing while he considers a request from Trump's lawyers that the conviction be thrown out in light of the Supreme Court ruling in July that an ex-president has broad immunity from prosecution. In Georgia, Trump faces racketeering charges over his efforts to subvert the 2020 election results in the southern state, but that case will likely be frozen while he is in office. cl/bgs
None
Woot Has Over 40 Nintendo Switch Game Deals, Including Many Of The Best Exclusives And Rare Finds - GameSpotHyderabad: The South Zone Task Force arrested 12 people who were found gambling at Khalikhabar. Police seized Rs 1.2 lakh in cash from them. Acting on specific information, the team raided an open place near the Musi River at Kalikhabar and found notorious gambling organizer Basheer inviting participants to the place and allowing them to participate in a three-card gambling den after collecting a whooping commission. Along with cash, police seized playing cards and mobile phones. According to sources, Khadeer and Basheer are coordinating and organizing gambling at different places in the city and running a big network. One of the organizers claims to be a driver working with senior bureaucrats and assuring the participants of managing the police with his connections.Across the Middle East and beyond, the fall of Syria’s authoritarian government at the hands of jihadi militants set off waves of jubilation, trepidation and alarm. Expatriate Syrians and many residents across the Middle East exulted at the overthrow of a leader who led his country through 14 years of civil strife that left half a million Syrians dead and displaced millions to countries around the world. While others are worried about further instability rocking a region already in turmoil. Governments — whether allies or opponents of Bashar Assad — scrambled to absorb the sudden, stunning development and assess the implications for the Middle East and the world. Mr Biden credited action by the US and its allies for weakening Syria’s backers — Russia, Iran and Hezbollah. He said “for the first time” that they could no longer defend Mr Assad’s grip on power. “Our approach has shifted the balance of power in the Middle East,” Mr Biden said. The US has about 900 troops in Syria, including US forces working with Kurdish allies in the opposition-held north east to prevent any resurgence of the Islamic State group. In Lebanon, thousands of Syrians headed for the Masnaa border crossing to return to their home country, despite the uncertainty. “Anything is better than Bashar,” said Sami Abdel-Latif, a refugee from Hama who was heading back to join his wife and four children. “This is a feeling we’ve been waiting 14 years for,” said Malak Matar, who was preparing to return to the capital of Damascus. Now, he said, “Syrians have to create a state that is well organised and take care of their country.” Many citizens in Syria’s neighbouring countries reacted with joy to the news Mr Assad was gone. “I believe that the future is beautiful and prosperous for the Syrians,” he said. Syria’s neighbours stepped up security along their borders. Lebanon said it was closing all but one of its land border crossings with Syria. Jordan also closed a border crossing. Iran, a key ally of Mr Assad, said the Syrian people should decide their country’s future “without destructive, coercive foreign intervention”. The Foreign Ministry in Tehran said Iran supports Syria’s unity and national sovereignty and hopes to see “the end of military conflicts, the prevention of terrorist activities and the start of a national dialogue” with the participation of all groups. Egypt’s foreign ministry urged a “comprehensive political process” to establish a new era of peace in the war-torn country. The head of Yemen’s internationally recognised government welcomed the fall of Mr Assad as “a historic moment”. Turkey has backed anti-Assad militant groups in Syria and could play a key role in what happens next. Turkish Foreign Minister Hakan Fidan said the fall of Assad brought “hope” and he called on the world to help “unite and reconstruct” Syria. In Europe, many governments welcomed Mr Assad’s departure while urging a rapid return to stability. France’s foreign ministry welcomed the fall of Mr Assad, saying “the Syrian people have suffered too much”. British Prime Minister Sir Keir Starmer also welcomed the end of Mr Assad’s “barbaric regime”. “We call on all sides to protect civilians and minorities and ensure essential aid can reach the most vulnerable in the coming hours and days,” he said. United Nations Secretary-General Antonio Guterres also called for calm and urged work to ensure an “orderly political transition to renewed institutions”. State media later reported that Mr Assad was in Moscow with his family and they had been granted asylum. Foreign Minister Andrii Sybiha of Ukraine, which is at war with Russia, wrote on X that the ousted Syrian leader had suffered the fate of “all dictators who bet on (Russian President Vladimir) Putin. He always betrays those who rely on him”.Notre Dame welcomes back public for mass after five-year refit
George Kresge Jr., who wowed talk show audiences as the The Amazing Kreskin, diesKirklees Council set to increase council tax by 4.99 per cent and agree Dewsbury Blueprint plans as budget proposals revealed
Electric vehicles are growing in popularity but still make up a small percentage of total car sales. More than two decades of vehicle and infrastructure development have yielded only a 6.8% market share for EVs in the United States. Part of the problem is range anxiety — owners’ fear that they won’t be able to get where they need to go on a full charge. But as charging stations proliferate and EV range increases, that fear should fade. To help, Edmunds’ experts have compiled a list of five of the highest-range electric vehicles available for less than $50,000. The vehicles on this list are specific trims and configurations that offer the most range for the least money. The range ratings listed below are a combination of EPA and manufacturer estimates. Edmunds does its own independent EV range testing, which can be found on its website. Prices listed here include destination charges. With an ultra-low starting price, the Equinox EV is both affordable and practical. Chevy estimates its range at 319 miles. That, of course, is not a formal EPA estimate, but it’s identical to what the EPA estimated for the Equinox with this powertrain for 2024. The big difference for 2025 is a significantly lower starting price for a car with fewer features and slightly more power. Still, the Equinox includes several meaningful driver assist features, such as automated emergency braking and rear parking sensors, as standard. Equinox LT FWD price: $34,995 A max 320-mile EPA range rating helps make Ford’s iconically named EV reasonably practical. The Mach-E charges slower than other EVs in this price range, but it’s more engaging to drive than many competitors. Its hatchback body and low ride height represent a practical middle ground between a sedan and an SUV. There are also multiple powertrains available, including a more powerful GT version and a shorter-range variant that costs less. Overall, the Mach-E represents an attractive, fun and utilitarian EV for the money. Mach-E Premium Extended Range RWD price: $48,990 With up to 342 miles of EPA-estimated range and a sub-$44,000 starting price, the Ioniq 6 is a masterfully utilitarian electric sedan. Part of its appeal is compatibility with the latest quick-charging technology, which Hyundai says allows it to charge from 10% to 80% in less than 18 minutes. It can also fully replenish its battery on a home charger in less than seven hours. Edmunds verified Hyundai’s charging claims, but as always, they are condition-dependent. Though the Ioniq’s styling may not be for everyone, there’s no denying the appeal of Hyundai’s 10-year/100,000-mile powertrain warranty. Ioniq 6 SE RWD price: $43,850 Tesla’s Model Y was among the first all-electric SUVs and it remains the standard bearer for small electric SUVs. It offers an EPA-estimated range of up to 320 miles. We also like the Y’s utility. There’s decent storage behind the second-row seats, a handy rear underfloor storage area and even a front trunk. You can also make the most of the Model Y’s range on road trips thanks to Tesla’s nationwide network of easy-to-use Supercharger fast charging stations. 2025 Model Y Long Range Rear-Wheel Drive price: $44,990 Tesla made big updates to its Model 3 for the 2024 model year. Tesla estimates that the Long Range Rear-Wheel Drive version can go 363 miles on a full charge. That’s an ample surplus of miles for most people’s needs. And the Model 3 has shown itself to be one of the most efficient EVs available, using less electrical power per mile driven than many competitors. What’s more, range is but one of the 3’s many merits. It accelerates quickly, handles well, and brings together luxury and affordability in a thoroughly modern design. 2024 Model 3 Long Range Rear-Wheel Drive price: $42,490 Every EV on this list offers more than 300 miles of range, which is as much as most people need. But it’s important to also keep in mind that maximum range can be reduced by cold weather, hilly terrain and aggressive driving styles. This story was provided to The Associated Press by the automotive website Edmunds. Josh Jacquot is a contributor at Edmunds.James Martin’s ‘gorgeous’ tomato roasted soup is the ‘perfect’ winter comfort dishCorporate governance foundation for success, sustainability of the telecoms industry in Nigeria
In the 2016 science fiction movie Arrival, a linguist is faced with the daunting task of deciphering an alien language consisting of palindromic phrases, which read the same backwards as they do forwards, written with circular symbols. As she discovers various clues, different nations around the world interpret the messages differently — with some assuming they convey a threat. If humanity ended up in such a situation today, our best bet may be to turn to research uncovering how artificial intelligence (AI) develops languages. But what exactly defines a language? Most of us use at least one to communicate with people around us, but how did it come about? Linguists have been pondering this very question for decades , yet there is no easy way to find out how language evolved . Language is ephemeral, it leaves no examinable trace in the fossil records. Unlike bones, we can't dig up ancient languages to study how they developed over time. While we may be unable to study the true evolution of human language, perhaps a simulation could provide some insights. That's where AI comes in — a fascinating field of research called emergent communication , which I have spent the last three years studying. To simulate how language may evolve, we give agents (AIs) simple tasks that require communication, like a game where one robot must guide another to a specific location on a grid without showing it a map. We provide (almost) no restrictions on what they can say or how — we simply give them the task and let them solve it however they want. Because solving these tasks requires the agents to communicate with each other, we can study how their communication evolves over time to get an idea of how language might evolve. Related: Father-daughter team decodes 'alien signal' from Mars that stumped the world for a year Similar experiments have been done with humans . Imagine you, an English speaker, are paired with a non-English speaker. Your task is to instruct your partner to pick up a green cube from an assortment of objects on a table. You might try to gesture a cube shape with your hands and point at grass outside the window to indicate the color green. Over time you'd develop a sort of proto-language together. Maybe you'd create specific gestures or symbols for "cube" and "green". Through repeated interactions, these improvised signals would become more refined and consistent, forming a basic communication system. This works similarly for AI. Through trial and error, they learn to communicate about objects they see, and their conversation partners learn to understand them. But how do we know what they're talking about? If they only develop this language with their artificial conversation partner and not with us, how do we know what each word means? After all, a specific word could mean "green", "cube", or worse — both. This challenge of interpretation is a key part of my research. Cracking the code The task of understanding AI language may seem almost impossible at first. If I tried speaking Polish (my mother tongue) to a collaborator who only speaks English, we couldn't understand each other or even know where each word begins and ends. The challenge with AI languages is even greater, as they might organise information in ways completely foreign to human linguistic patterns. Fortunately, linguists have developed sophisticated tools using information theory to interpret unknown languages. Just as archaeologists piece together ancient languages from fragments, we use patterns in AI conversations to understand their linguistic structure. Sometimes we find surprising similarities to human languages, and other times we discover entirely novel ways of communication . These tools help us peek into the "black box" of AI communication, revealing how artificial agents develop their own unique ways of sharing information. My recent work focuses on using what the agents see and say to interpret their language. Imagine having a transcript of a conversation in a language unknown to you, along with what each speaker was looking at. We can match patterns in the transcript to objects in the participant's field of vision, building statistical connections between words and objects. For example, perhaps the phrase "yayo" coincides with a bird flying past — we could guess that "yayo" is the speaker's word for "bird". Through careful analysis of these patterns, we can begin to decode the meaning behind the communication. In the latest paper by me and my colleagues, to appear in the conference proceedings of Neural Information Processing Systems (NeurIPS), we show that such methods can be used to reverse-engineer at least parts of the AIs' language and syntax, giving us insights into how they might structure communication. Aliens and autonomous systems How does this connect to aliens ? The methods we're developing for understanding AI languages could help us decipher any future alien communications. If we are able to obtain some written alien text together with some context (such as visual information relating to the text), we could apply the same statistical tools to analyze them. The approaches we're developing today could be useful tools in the future study of alien languages, known as xenolinguistics. But we don't need to find extraterrestrials to benefit from this research. There are numerous applications , from improving language models like ChatGPT or Claude to improving communication between autonomous vehicles or drones . By decoding emergent languages, we can make future technology easier to understand. Whether it's knowing how self-driving cars coordinate their movements or how AI systems make decisions, we're not just creating intelligent systems — we're learning to understand them. This edited article is republished from The Conversation under a Creative Commons license. Read the original article .Utah Hockey Club Walks to Arena After Bus Gets Stuck in Toronto Traffic
California Water Service Group exec Michael Luu sells $50,727 in stockGeorge Kresge Jr., who wowed talk show audiences as the The Amazing Kreskin, diesThe spiritual heart of Paris awakens: Notre Dame hosts first Mass since 2019 fire
TEMPE, Ariz. (AP) — Miguel Tomley scored 28 points as Weber State beat Pepperdine 68-53 in the Desert Division championship game of the Arizona Tip-Off on Saturday night. Tomley shot 7 for 12 (6 for 7 from 3-point range) and 8 of 8 from the free-throw line for the Wildcats (4-4). Blaise Threatt added 21 points and seven rebounds. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.MENLO PARK, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Robinhood Markets, Inc. (“Robinhood”) (NASDAQ: HOOD) today reported select monthly operating data for November 2024: For definitions and additional information regarding these metrics, please refer to Robinhood’s full monthly metrics release, which is available on investors.robinhood.com . The information in this release is unaudited and the information for the months in the most recent fiscal quarter is preliminary, based on Robinhood’s estimates, and subject to completion of financial closing procedures. Final results for the most recent fiscal quarter, as reported in Robinhood’s quarterly and annual filings with the U.S. Securities and Exchange Commission (“SEC”), might vary from the information in this release. About Robinhood Robinhood Markets, Inc. (NASDAQ: HOOD) transformed financial services by introducing commission-free stock trading and democratizing access to the markets for millions of investors. Today, Robinhood lets you trade stocks, options, commodity interests, and crypto, invest for retirement, and earn with Robinhood Gold. Headquartered in Menlo Park, California, Robinhood puts customers in the driver's seat, delivering unprecedented value and products intentionally designed for a new generation of investors. Additional information about Robinhood can be found at www.robinhood.com . Robinhood uses the “Overview” tab of its Investor Relations website (accessible at investors.robinhood.com/overview ) and its Newsroom (accessible at newsroom.aboutrobinhood.com ), as means of disclosing information to the public in a broad, non-exclusionary manner for purposes of the U.S. Securities and Exchange Commission's (“SEC”) Regulation Fair Disclosure (Reg. FD). Investors should routinely monitor those web pages, in addition to Robinhood’s press releases, SEC filings, and public conference calls and webcasts, as information posted on them could be deemed to be material information. “Robinhood” and the Robinhood feather logo are registered trademarks of Robinhood Markets, Inc. All other names are trademarks and/or registered trademarks of their respective owners. Contacts Investor Relations ir@robinhood.com Media press@robinhood.com
Uber Stock Slides Again. Investors' Robotaxi Fears Grow After GM Shuts Down Cruise.Newmark Arranges $525 Million Refinancing for Flexible Living Apartment Portfolio Operated by SentralMid-American Conference football goes all in on November weeknights for the TV viewers
COPENHAGEN, Denmark--(BUSINESS WIRE)--Dec 8, 2024-- Genmab A/S (Nasdaq: GMAB): Genmab A/S (Nasdaq: GMAB) today announced results from the Phase 1b/2 EPCORE ® CLL-1 clinical trial evaluating epcoritamab (Abstract #883), a T-cell engaging bispecific antibody administered subcutaneously, demonstrated an overall response rate (ORR) of 61 percent and a complete response (CR) rate of 39 percent in difficult-to-treat adult patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) treated with epcoritamab monotherapy. These results, from the monotherapy expansion (EXP) cohort (n=23) of the trial, along with the first safety data from the optimization (OPT) cohort, were presented at the 66 th Annual Meeting and Exposition of the American Society of Hematology (ASH), during the ASH Annual Meeting Press Program. The data will be presented during an oral session on December 9, 2024. In the EXP cohort, the median time to response was two (2.0) months and the median time to CR was 5.6 months. Among all patients in the cohort, median progression-free survival (PFS) was 12.8 months and median overall survival (OS) was not reached (median follow-up was 22.8 months). An estimated 65 percent of patients were alive at 15 months. Among 12 responders evaluable for minimal residual disease (MRD) by next-generation sequencing in peripheral blood, nine patients (75 percent) had undetectable MRD. The most frequent non-hematologic treatment-emergent adverse events (TEAEs) in the EXP cohort were cytokine release syndrome (CRS; 96 percent), diarrhea (48 percent), peripheral edema (48 percent), fatigue (43 percent), and injection-site reaction (43 percent). Cytopenias were common (anemia, 65 percent; thrombocytopenia, 65 percent; neutropenia, 48 percent); however, most patients had baseline anemia and thrombocytopenia, suggesting that these events were largely disease-related. Three cases of immune effector cell-associated neurotoxicity syndrome (ICANS) were reported (one Grade 1; two Grade 2), and there was one clinical tumor lysis syndrome (CTLS) case (Grade 2). These cases did not lead to treatment discontinuation. Four fatal TEAEs occurred - two cases of pneumonia, one case of sepsis and one case of squamous cell carcinoma of the skin. The EXP cohort followed a 2-step step-up dose regimen, and CRS was manageable and primarily low grade (9 percent Grade 1, 70 percent Grade 2, 17 percent Grade 3). In the first data from the separate OPT cohort, which followed a 3-step step-up dose regimen, CRS severity was substantially reduced with only low-grade events (71 percent Grade 1, 12 percent Grade 2). In both cohorts, CRS events primarily occurred following the first full dose, and none led to treatment discontinuation. No ICANS or CTLS cases were reported in the OPT cohort. “These EPCORE CLL-1 data are encouraging, especially as the majority of patients were heavily pre-treated with at least four lines of therapy,” said Alexey Danilov, MD, PhD, Marianne and Gerhard Pinkus, Professor and Director of Early Clinical Therapeutics and Associate Director of the Toni Stephenson Lymphoma Center, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope. “Despite progress in treating chronic lymphocytic leukemia, there remains a tremendous need for additional therapeutic options for high-risk patients whose disease has progressed following standard chemoimmunotherapy and targeted therapies.” Additional data from the EXP cohort showed high response rates in patients with high-risk factors treated with epcoritamab, including TP53 aberrations, IGHV-unmutated disease and double-exposed disease – prognostic markers that are associated with disease progression and decreased survival. i,ii,iii In patients with TP53 aberrations (n=15), the ORR was 67 percent with a CR of 33 percent. Among patients with IGHV-unmutated disease (n=16), the ORR was 63 percent, and the CR was 44 percent. In double-refractory patients, the ORR was 53 percent, and the CR was 37 percent. All patients in the trial had prior chemoimmunotherapy, and most patients had previously received targeted therapies such as BTK and BCL2 inhibitors (double-exposed) and had high-risk disease characteristics. “Chronic lymphocytic leukemia is incurable, and patients often need a variety of treatments throughout their lifetime, especially if their disease has high-risk prognostic factors, has relapsed or has become refractory to the current standard-of-care, including targeted therapies,” said Dr. Judith Klimovsky, Executive Vice President & Chief Development Officer, Genmab. “These early data show the potential therapeutic applicability of epcoritamab in relapsed or refractory chronic lymphocytic leukemia, and further reinforce the potential of epcoritamab as a core therapy for the treatment of B-cell malignancies.” Use of epcoritamab in CLL is not approved in the U.S. or in the EU or in any other territory. The safety and efficacy of epcoritamab for use in CLL have not been established. About Chronic Lymphocytic Leukemia (CLL) Chronic lymphocytic leukemia (CLL) is the most prevalent type of leukemia, affecting over 200,000 people in the United States alone. iv Chronic lymphocytic leukemia can be classified as either slow growing (indolent) or fast growing (aggressive). v CLL is incurable, and many patients will likely relapse and progress on frontline therapies. vi Most patients will experience consecutive episodes of disease progression and will require several lines of treatment in their lifetime. vii,viii About the EPCORE ® CLL-1 Trial EPCORE ® CLL-1 is a Phase 1b/2, open-label, multi-center trial to evaluate the safety and preliminary efficacy of epcoritamab as a monotherapy and in combination with standard of care agents in patients with difficult-to-treat relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), R/R small lymphocytic lymphoma (SLL) and Richter's Syndrome (RS). The trial consists of two parts: a dose-escalation phase (Phase 1b) and an expansion phase (Phase 2). Patients with RS are only included in the expansion phase. The primary objective of Phase 1b is to determine the recommended Phase 2 dose and the maximum tolerated dose as well as establish the safety profile of epcoritamab monotherapy and epcoritamab plus venetoclax in participants with R/R CLL. The purpose of Phase 2 is to assess and evaluate the preliminary efficacy, safety and tolerability profiles of epcoritamab monotherapy and epcoritamab plus venetoclax for patients with R/R CLL and SLL. Additionally, epcoritamab monotherapy and combination therapy will be evaluated in patients with RS to assess their efficacy, safety and tolerability profiles. More information on this trial can be found at https://www.clinicaltrials.gov/ (NCT: 04623541). About Epcoritamab Epcoritamab is an IgG1-bispecific antibody created using Genmab's proprietary DuoBody ® technology and administered subcutaneously. Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response toward target cell types. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T-cell-mediated killing of CD20+ cells. ix Epcoritamab (approved under the brand name EPKINLY ® in the U.S. and Japan, and TEPKINLY ® in the EU) has received regulatory approval in certain lymphoma indications in several territories. Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies' oncology collaboration. The companies will share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization. Both companies will pursue additional international regulatory approvals for the investigational R/R FL indication and additional approvals for the R/R DLBCL indication. Genmab and AbbVie continue to evaluate the use of epcoritamab as a monotherapy, and in combination, across lines of therapy in a range of hematologic malignancies. This includes five ongoing Phase 3, open-label, randomized trials including a trial evaluating epcoritamab as a monotherapy in patients with R/R DLBCL compared to investigator's choice chemotherapy ( NCT04628494 ), a trial evaluating epcoritamab in combination with R-CHOP in adult patients with newly diagnosed DLBCL ( NCT05578976 ), a trial evaluating epcoritamab in combination with rituximab and lenalidomide (R 2 ) in patients with R/R FL ( NCT05409066 ), a trial evaluating epcoritamab in combination with rituximab and lenalidomide (R 2 ) compared to chemoimmunotherapy in patients with previously untreated FL ( NCT06191744 ), and a trial evaluating epcoritamab in combination with lenalidomide compared to chemotherapy infusion in patients with R/R DLBCL ( NCT06508658 ). The safety and efficacy of epcoritamab has not been established for these investigational uses. Please visit www.clinicaltrials.gov for more information. EPKINLY ® (epcoritamab-bysp) U.S. INDICATIONS & IMPORTANT SAFETY INFORMATION What is EPKINLY? EPKINLY is a prescription medicine used to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, or follicular lymphoma (FL) that has come back or that did not respond to previous treatment after receiving 2 or more treatments. EPKINLY is approved based on patient response data. Studies are ongoing to confirm the clinical benefit of EPKINLY. It is not known if EPKINLY is safe and effective in children. Important Warnings—EPKINLY can cause serious side effects, including: People with DLBCL or high-grade B-cell lymphoma should be hospitalized for 24 hours after receiving their first full dose of EPKINLY on day 15 of cycle 1 due to the risk of CRS and neurologic problems. Tell your healthcare provider or get medical help right away if you develop a fever of 100.4°F (38°C) or higher; dizziness or lightheadedness; trouble breathing; chills; fast heartbeat; feeling anxious; headache; confusion; shaking (tremors); problems with balance and movement, such as trouble walking; trouble speaking or writing; confusion and disorientation; drowsiness, tiredness or lack of energy; muscle weakness; seizures; or memory loss. These may be symptoms of CRS or neurologic problems. If you have any symptoms that impair consciousness, do not drive or use heavy machinery or do other dangerous activities until your symptoms go away. EPKINLY can cause other serious side effects, including: Your healthcare provider will monitor you for symptoms of CRS, neurologic problems, infections, and low blood cell counts during treatment with EPKINLY. Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects. Before you receive EPKINLY, tell your healthcare provider about all your medical conditions, including if you have an infection, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. If you receive EPKINLY while pregnant, it may harm your unborn baby. If you are a female who can become pregnant, your healthcare provider should do a pregnancy test before you start treatment with EPKINLY and you should use effective birth control (contraception) during treatment and for 4 months after your last dose of EPKINLY. Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EPKINLY. Do not breastfeed during treatment with EPKINLY and for 4 months after your last dose of EPKINLY. In DLBCL or high-grade B-cell lymphoma, the most common side effects of EPKINLY include CRS, tiredness, muscle and bone pain, injection site reactions, fever, stomach-area (abdominal) pain, nausea, and diarrhea. The most common severe abnormal laboratory test results include decreased white blood cells, decreased red blood cells, and decreased platelets. In follicular lymphoma the most common side effects of EPKINLY include injection site reactions, CRS, COVID-19, tiredness, upper respiratory tract infections, muscle and bone pain, rash, diarrhea, fever, cough, and headache. The most common severe abnormal laboratory test results include decreased white blood cells and decreased red blood cells. These are not all of the possible side effects of EPKINLY. Call your doctor for medical advice about side effects. You are encouraged to report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch or to Genmab US, Inc. at 1-855-4GENMAB (1-855-443-6622). Please see Full Prescribing Information and Medication Guide , including Important Warnings. Globally, prescribing information varies; refer to the individual country product label for complete information. About Genmab Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO ® ) antibody medicines. Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X . This Media Release contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov . Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. Genmab A/S and/or its subsidiaries own the following trademarks: Genmab ®; the Y-shaped Genmab logo ®; Genmab in combination with the Y-shaped Genmab logo ®; HuMax ®; DuoBody ®; HexaBody ®; DuoHexaBody ®, HexElect ® and KYSOTM. EPCORE ®, EPKINLY ®, TEPKINLY ® and their designs are trademarks of AbbVie Biotechnology Ltd. i Campo, et al. TP53 Aberrations in Chronic Lymphocytic Leukemia: An Overview of the Clinical Implications of Improved Diagnostics. Haematologica . 2018 Nov 15;103(12):1956–1968. https://haematologica.org/article/view/8691 . ii Galieni, et al. Unmutated IGHV at Diagnosis in Patients With Early Stage CLL Independently Predicts for Shorter Follow-Up Time to First Treatment (TTFT). Leukemia Research. 2024. https://doi.org/10.1016/j.leukres.2024.107541 . iii Zuber, et al. Efficacy and Effectiveness Outcomes of Treatments for Double-Exposed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients: A Systematic Literature Review. Cancer Medicine . 2024. https://doi.org/10.1002/cam4.70258 . iv Fedele, et al. Chronic Lymphocytic Leukemia: Time to Care for the Survivors. Journal of Clinical Oncology . 2024. https://ascopubs.org/doi/10.1200/JCO.23.02738 . v Penn Medicine. Chronic Lymphocytic Leukemia (CLL). Accessed November 2024. https://www.pennmedicine.org/cancer/types-of-cancer/leukemia/types-of-leukemia/chronic-lymphocytic-leukemia . vi Odetola, et al. Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). Curr Hematol Malig Rep . 2023 Jun 6:1–14. doi: 10.1007/s11899-023-00700-z vii Moreno, Carol. Standard Treatment Approaches for Relapsed/Refractory Chronic Lymphocytic Leukemia After Frontline Chemoimmunotherapy. Hematology Am Soc Hematol Educ Program . 2020 Dec 4;2020(1):33-40. doi: 10.1182/hematology.2020000086. viii Leukemia & Lymphoma Society. Relapsed and Refractory CLL. Accessed November 2024. https://www.lls.org/leukemia/chronic-lymphocytic-leukemia/treatment/relapsed-and-refractory . ix Engelberts PJ, et al. DuoBody-CD3xCD20 Induces Potent T-Cell-Mediated Killing of Malignant B Cells in Preclinical Models and Provides Opportunities for Subcutaneous Dosing. EBioMedicine . 2020;52:102625. doi: 10.1016/j.ebiom.2019.102625. View source version on businesswire.com : https://www.businesswire.com/news/home/20241208951291/en/ CONTACT: David Freundel, Senior Director, Global R&D & Portfolio Communications T: +1 609 430 2481; E:dafr@genmab.com Andrew Carlsen, Vice President, Head of Investor Relations T: +45 3377 9558; E:acn@genmab.com KEYWORD: DENMARK EUROPE INDUSTRY KEYWORD: RESEARCH FDA CLINICAL TRIALS BIOTECHNOLOGY HEALTH PHARMACEUTICAL OTHER SCIENCE SCIENCE ONCOLOGY SOURCE: Genmab A/S Copyright Business Wire 2024. PUB: 12/08/2024 11:00 AM/DISC: 12/08/2024 11:02 AM http://www.businesswire.com/news/home/20241208951291/enDetroit's iconic Renaissance Center could see 2 towers razed in $1.6B redevelopment plan